In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.70, marking a -3.29% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%.

In addition to being early to the defense tech and AI trends, Lux has realized significant exits from its investment in AI ...

We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was one ...

Peter Krull, director of Earth Equity Advisors, discusses why he's bullish on renewable energy and shares his top clean ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...

Eli Lilly is a well-established pharmaceutical company with a portfolio of products that consistently generate revenue and ...

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts.

Wall Street ends 2026 positively with tech stocks dominating, but concerns over valuations drive interest in smaller AI stocks for 2026.

Abstract: Renewable energy sources and electric vehicles provide an effective way to reduce the energy cost of an enterprise microgrid. However, the uncertainties of renewable energy sources and the ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...